Results 171 to 180 of about 18,037 (235)

Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
Many pathophysiological pathways associated with cardiovascular diseases involve multiple drug targets. This article reviews recent advances in the development of pharmacological compounds capable of simultaneously modulating multiple mechanisms. Multitarget drugs offer a promising therapeutic approach for complex cardiovascular disorders, including ...
Gyuzel Y. Mitronova, Vladimir N. Belov, Constanze Schmidt, Stephan E. Lehnart   +3 more
wiley   +1 more source

Management Strategies for Potassium Levels During Non-steroidal Mineralocorticoid Receptor Antagonist Therapy: A Comprehensive Review. [PDF]

Electrolyte Blood Press
Son HE.
europepmc   +1 more source

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta-Analysis. [PDF]

J Am Heart Assoc
Huang CW, Huang TY, Yang YF, Chang LY, Tu YK, Wu VC, Chen JY.   +6 more
europepmc   +1 more source

Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis. [PDF]

Diabetes Care
Rossing P, Bakris G, Perkovic V, Pratley R, Tuttle KR, Mahaffey KW, Idorn T, Belmar N, Bosch-Traberg H, Rasmussen S, Busch RS, Schmieder RE, Gillard P, Mann JFE, FLOW Investigator Group .   +14 more
europepmc   +1 more source

Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity. [PDF]

J Clin Med Res
Okamura K, Matsushima M, Takamiya Y, Okuda T, Sako H, Udo A, Taniguchi K, Morisaki S, Imamura I, Urata H, Miura SI.   +10 more
europepmc   +1 more source

Non-steroidal mineralocorticoid receptor antagonist finerenone inhibits peritoneal fibrosis induced by high-glucose dialysate via regulating enhancer of zeste homolog 2 (EZH2) expression. [PDF]

Ren Fail
Chen D, Shu J, Zhang X, Wang S, Sun J, Chong N, Sun Z, Xu Y, Wang Q.   +8 more
europepmc   +1 more source

Prenatal exposure to the mineralocorticoid receptor antagonist spironolactone disrupts hippocampal area CA2 connectivity and alters behavior in mice. [PDF]

Neuropsychopharmacology
Jones SM, Sleiman SJ, McCann KE, Jarmusch AK, Alexander GM, Dudek SM.   +5 more
europepmc   +1 more source

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment. [PDF]

Eur J Drug Metab Pharmacokinet
McCabe J, Zhang J, Yang F, Benn V.
europepmc   +1 more source